Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.

ABSTRACT:

Background

Anti-programmed cell death 1 (PD-1) antibody combined with chemotherapy simultaneously is regarded as the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) by current clinical guidelines. Different immune statuses induced by chemotherapy considerably affect the synergistic effects of the chemo-anti-PD-1 combination. Therefore, it is necessary to determine the optimal timing of combination treatment administration.

Methods

The dynamic immune status induced by chemotherapy was observed in paired peripheral blood samples of patients with NSCLC using flow cytometry and RNA sequencing. Ex vivo studies and metastatic lung carcinoma mouse models were used to evaluate immune activity and explore the optimal combination timing. A multicenter

SUBMITTER: Huo Y 

PROVIDER: S-EPMC11667274 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature